Gene Patents Would Be Limited Under HHS Advisory Panel Proposal
This article was originally published in The Gray Sheet
Executive Summary
An HHS advisory committee is proposing that anyone who uses a gene patent to make or sell a diagnostic test or for research purposes should not be liable for infringement
You may also be interested in...
Patently Unconstitutional? Lawsuit Proceeds Over BRCA Gene Patents
Researchers challenging the patents on the BRCA1 and BRCA2 breast cancer genes won the first round in their suit against the U.S. Patent and Trademark Office and molecular diagnostics firm Myriad Genetics when a court denied the defendants' request to dismiss the case
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.